A clinical trial update was posted on October 2, 2026, for a study involving nesiritide-related research context, registered under ID NCT07755904. The trial is titled "BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy." It is listed as a Phase 3 study. Its current status is recruiting, meaning the trial is actively enrolling participants as of the update date. The study compares BHB-1893 to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy. No results have been posted as part of this update. No efficacy or safety outcomes are stated in the available data. This brief reflects only the status and design details provided in the trial registration record. Readers should note that nesiritide carries an unapproved research status, and any connection to this specific trial is not detailed beyond the provided identifiers. For additional context on nesiritide, including its classification and research background, readers can consult the compound overview.
Phase 3 Trial Update: BHB-1893 vs Metoprolol in HCM, Recruiting
See the full nesiritide overview
Source: https://clinicaltrials.gov/study/NCT07755904